These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35143374)

  • 1. Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis.
    Sanders DB; Wu R; O'Neil T; Elbert A; Petren K; Jain R; Ren CL
    Ann Am Thorac Soc; 2022 Oct; 19(10):1697-1703. PubMed ID: 35143374
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis.
    Gushue C; Eisner M; Bai S; Johnson T; Holtzlander M; McCoy K; Sheikh S
    Pediatr Pulmonol; 2023 Aug; 58(8):2308-2316. PubMed ID: 37222417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry.
    Sutharsan S; Dillenhoefer S; Welsner M; Stehling F; Brinkmann F; Burkhart M; Ellemunter H; Dittrich AM; Smaczny C; Eickmeier O; Kappler M; Schwarz C; Sieber S; Naehrig S; Naehrlich L;
    Lancet Reg Health Eur; 2023 Sep; 32():100690. PubMed ID: 37554663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.
    Sheikh S; Britt RD; Ryan-Wenger NA; Khan AQ; Lewis BW; Gushue C; Ozuna H; Jaganathan D; McCoy K; Kopp BT
    Pediatr Pulmonol; 2023 Mar; 58(3):825-833. PubMed ID: 36444736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.
    Milo F; Ciciriello F; Alghisi F; Tabarini P
    J Cyst Fibros; 2023 May; 22(3):414-419. PubMed ID: 36549989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations.
    Livnat G; Dagan A; Heching M; Shmueli E; Prais D; Yaacoby-Bianu K; Stein N; Mei-Zahav M; Gur M; Cohen-Cymberknoh M; Shteinberg M
    J Cyst Fibros; 2023 May; 22(3):450-455. PubMed ID: 36372699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
    Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
    Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
    [No Abstract]   [Full Text] [Related]  

  • 9. Suicide attempts in adolescents with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Arslan M; Chalmers S; Rentfrow K; Olson JM; Dean V; Wylam ME; Demirel N
    J Cyst Fibros; 2023 May; 22(3):427-430. PubMed ID: 36759252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor.
    Gruber W; Stehling F; Blosch C; Dillenhoefer S; Olivier M; Brinkmann F; Koerner-Rettberg C; Sutharsan S; Mellies U; Taube C; Welsner M
    Front Sports Act Living; 2024; 6():1284878. PubMed ID: 38463712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey assessing the impact of COVID-19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis.
    Sakon C; Vogt H; Brown CD; Tillman EM
    Pediatr Pulmonol; 2023 Mar; 58(3):662-664. PubMed ID: 36482831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study.
    Fila L; Grandcourtova A; Bilkova A; Drevinek P
    Front Pharmacol; 2023; 14():1178009. PubMed ID: 37332357
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of elexacaftor-tezacaftor-ivacaftor on daily treatment burden and airflow obstruction in adults with cystic fibrosis.
    Tiotiu A; Ioan I; Billon Y
    Pulm Pharmacol Ther; 2023 Oct; 82():102248. PubMed ID: 37562640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
    Dreano E; Burgel PR; Hatton A; Bouazza N; Chevalier B; Macey J; Leroy S; Durieu I; Weiss L; Grenet D; Stremler N; Ohlmann C; Reix P; Porzio M; Roux Claude P; Rémus N; Douvry B; Montcouquiol S; Cosson L; Mankikian J; Languepin J; Houdouin V; Le Clainche L; Guillaumot A; Pouradier D; Tissot A; Priou P; Mély L; Chedevergne F; Lebourgeois M; Lebihan J; Martin C; Zavala F; Da Silva J; Lemonnier L; Kelly-Aubert M; Golec A; Foucaud P; Marguet C; Edelman A; Hinzpeter A; de Carli P; Girodon E; Sermet-Gaudelus I; Pranke I;
    Eur Respir J; 2023 Oct; 62(4):. PubMed ID: 37696564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis.
    Casey M; Gabillard-Lefort C; McElvaney OF; McElvaney OJ; Carroll T; Heeney RC; Gunaratnam C; Reeves EP; Murphy MP; McElvaney NG
    Thorax; 2023 Aug; 78(8):835-839. PubMed ID: 37208188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI.
    Gill ER; Bartlett LE; Milinic T; Burdis N; Pilewski JM; Dunitz JM; Kapnadak SG; Goss CH; Ramos KJ
    J Cyst Fibros; 2024 Jan; 23(1):161-164. PubMed ID: 38008684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.
    Zhang S; Shrestha CL; Robledo-Avila F; Jaganathan D; Wisniewski BL; Brown N; Pham H; Carey K; Amer AO; Hall-Stoodley L; McCoy KS; Bai S; Partida-Sanchez S; Kopp BT
    Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 36265882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S
    Front Immunol; 2023; 14():1107437. PubMed ID: 36875141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the
    Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Ferrillo L; Pepe A; Francalanci M; Taccetti G; Buonaurio S; Celardo A; Salvadori L; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.